Admission to AIM for Synairgen and a £10.5 million placing

Client

Synairgen Plc

Date

October 2004
Acted for Synairgen Plc, a drug discovery company specialising in respiratory diseases (asthma and COPD), on its admission to AIM and £10.5 million placing in October 2004.